RiverVest is a leading venture capital firm building life science companies to address significant unmet needs of patients and deliver consistently strong returns to investors.
Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile – 3/23/2023
Wugen, Inc. Announces CEO Transition — Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer – 3/21/2023
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies – 3/14/2023
Mirum Pharmaceuticals Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older- 3/14/2023
Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis – 2/14/2023
Spruce Biosciences Announces $53.6 Million Private Placement Financing – 2/9/2023
Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD) – 1/31/2023
Alleviant Medical Closes $75M in Financing; Receives FDA IDE Approval for Pivotal Clinical Trial – 1/26/2023
Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG – 1/9/2023
Spruce Biosciences and Karen Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan – 1/5/2023
Mirum Pharmaceuticals‘ LIV MARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older – 12/13/2022
Subscribe to our newsletter